Literature DB >> 28903184

Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury.

Min Shen1, Shan Wang1, Xin Wen1, Xin-Rui Han1, Yong-Jian Wang1, Xiu-Min Zhou2, Man-He Zhang2, Dong-Mei Wu3, Jun Lu4, Yuan-Lin Zheng5.   

Abstract

OBJECTIVE: This study aims to explore the neuroprotective effects of dexmedetomidine (Dex) in rats suffering from traumatic brain injury (TBI) via the PI3K/Akt/mTOR signaling pathway.
METHODS: A weight drop model was performed for TBI model establishment. A total of 150 Sprague Dawley rats were selected and assigned into control, sham, TBI, TBI+Dex, TBI+LY294002 (LY) and TBI+Dex+LY groups. Modified Neurological Severity Score (mNSS) was conducted in order to evaluate the neurological injury. The water content in brain tissues was measured. The expressions of PI3K/Akt/mTOR signaling pathway-related proteins, tight junction proteins (ZO-1 and Claudin-5) and autophagy proteins (LC3 I/II and Beclin-1) were detected using Western blot assay. A TUNEL assay was applied for cell apoptosis, immunofluorescence was employed for the detection of the positive expression of LC3, and ELISA was applied for detection of levels of inflammatory factors [tumor necrosis factor-alph (TNF-a), interleukin-1β (IL-1β), interferon-γ (INF-γ) as well as IL-6], respectively.
RESULTS: Compared with the control group, the other four groups exhibited increased mNSS, brain water content, expression of LC3, TNF-a, IL-1β, INF-γ and IL-6, and positive expression of LC3, expression of LC3 I/II and Beclin-1, but decreased expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5. Compared with the TBI group, the TBI+Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1β, INF-γ and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI+LY group. The TBI+Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1β, INF-γ and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI+LY group, as compared with the TBI+Dex+LY group.
CONCLUSION: The data shows that Dex exerts a neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with TBI.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Autophagy; Dexmedetomidine; Neuroprotective effect; PI3K/Akt/mTOR signaling pathway; Traumatic brain injury

Mesh:

Substances:

Year:  2017        PMID: 28903184     DOI: 10.1016/j.biopha.2017.08.125

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  36 in total

1.  Traumatic Brain Injury Temporal Proteome Guides KCC2-Targeted Therapy.

Authors:  Pavel N Lizhnyak; Pretal P Muldoon; Pallavi P Pilaka; John T Povlishock; Andrew K Ottens
Journal:  J Neurotrauma       Date:  2019-07-31       Impact factor: 5.269

2.  Modeling Controlled Cortical Impact Injury in 3D Brain-Like Tissue Cultures.

Authors:  Volha Liaudanskaya; Joon Yong Chung; Craig Mizzoni; Nicolas Rouleau; Alexander N Berk; Limin Wu; Julia A Turner; Irene Georgakoudi; Michael J Whalen; Thomas J F Nieland; David L Kaplan
Journal:  Adv Healthc Mater       Date:  2020-05-13       Impact factor: 9.933

3.  Neuroprotective effect of vildagliptin against cerebral ischemia in rats.

Authors:  Salma A El-Marasy; Rehab F Abdel-Rahman; Reham M Abd-Elsalam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-18       Impact factor: 3.000

Review 4.  Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug.

Authors:  Michał Wiciński; Oskar Puk; Bartosz Malinowski
Journal:  Neurochem Res       Date:  2020-11-30       Impact factor: 3.996

5.  Tailored Therapeutic Doses of Dexmedetomidine in Evolving Neuroinflammation after Traumatic Brain Injury.

Authors:  Dicle Karakaya; Canan Cakir-Aktas; Sennur Uzun; Figen Soylemezoglu; Melike Mut
Journal:  Neurocrit Care       Date:  2021-11-16       Impact factor: 3.210

Review 6.  Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets.

Authors:  Komal Thapa; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur
Journal:  J Mol Neurosci       Date:  2021-05-06       Impact factor: 3.444

7.  Multi-Dimensional Mapping of Brain-Derived Extracellular Vesicle MicroRNA Biomarker for Traumatic Brain Injury Diagnostics.

Authors:  Jina Ko; Matthew Hemphill; Zijian Yang; Kryshawna Beard; Emily Sewell; Jamie Shallcross; Melissa Schweizer; Danielle K Sandsmark; Ramon Diaz-Arrastia; Junhyong Kim; David Meaney; David Issadore
Journal:  J Neurotrauma       Date:  2019-05-06       Impact factor: 4.869

Review 8.  Autophagy in Traumatic Brain Injury: A New Target for Therapeutic Intervention.

Authors:  Li Zhang; Handong Wang
Journal:  Front Mol Neurosci       Date:  2018-06-05       Impact factor: 5.639

9.  Dexmedetomidine attenuates traumatic brain injury: action pathway and mechanisms.

Authors:  Dong Wang; Xin Xu; Yin-Gang Wu; Li Lyu; Zi-Wei Zhou; Jian-Ning Zhang
Journal:  Neural Regen Res       Date:  2018-05       Impact factor: 5.135

10.  Neuroprotective effects of dexmedetomidine on traumatic brain injury: Involvement of neuronal apoptosis and HSP70 expression.

Authors:  Man-He Zhang; Xiu-Min Zhou; Jian-Zhong Cui; Kai-Jie Wang; Yan Feng; Hong-Ao Zhang
Journal:  Mol Med Rep       Date:  2018-04-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.